The 23-valent pneumococcal polysaccharide vaccine is effective in elderly adults over 75 years old—Taiwan's PPV vaccination program
- 1 June 2015
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 33 (25), 2897-2902
- https://doi.org/10.1016/j.vaccine.2015.04.068
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine Against Community-Acquired Pneumonia in the General Population Aged >=60 Years: 3 Years of Follow-up in the CAPAMIS StudyClinical Infectious Diseases, 2014
- Antimicrobial susceptibility of bacterial pathogens associated with community-acquired respiratory tract infections in Asia: report from the Community-Acquired Respiratory Tract Infection Pathogen Surveillance (CARTIPS) study, 2009–2010International Journal of Antimicrobial Agents, 2011
- Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐AreaStreptococcus pneumoniaeResearch (CASPER) StudyClinical Infectious Diseases, 2009
- Etiology of community acquired pneumonia among adult patients requiring hospitalization in TaiwanRespiratory Medicine, 2005
- Additive preventive effect of influenza and pneumococcal vaccines in elderly personsEuropean Respiratory Journal, 2004
- Pneumococcal Vaccination in Older AdultsNew England Journal of Medicine, 2003
- Taiwan’s New National Health Insurance Program: Genesis And Experience So FarHealth Affairs, 2003
- Community-Acquired PneumoniaNew England Journal of Medicine, 1995
- The Protective Efficacy of Polyvalent Pneumococcal Polysaccharide VaccineNew England Journal of Medicine, 1991
- Inefficacy of pneumococcal vaccine in a high-risk populationAmerican Journal Of Medicine, 1987